Sequencing Xtandi – Possibly the ADT of the Future? An Interview with Dr. Bertrand Tombal
There was a recent interview in the Pharma Strategy Blog with Dr. Bertrand Tombal , an academic urologist in Belgium. Dr. Tomal discussed several of the new advances in the treatment od advanced prostate cancer [...]
From the 2013 2013 Genitourinary Cancers Symposium: High-Risk Prostate Cancer Treated with Pelvic Radiotherapy and 36 Versus 18 Months of Androgen Blockade
Men who are diagnosed with high risk prostate cancer, meaning they are more likely to develop advanced prostate cancer are usually treated with Radiotherapy (RT) and long term androgen blockade (AB). Currently, we do not [...]
Two More Provenge Related Abstracts from the 2013 ASCO GU Symposium
More on Sipuleucel-T (Provenge) from the 2013 The last two abstracts that I want to speak about that were presented at the conference that pertained to Provenge speak to its efficacy. The first looks at [...]
From the 2013 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium – News of Provenge
Currently in Orlando Florida the 2013 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium is in progress. There are a number of very interesting abstracts that pertain to those of us who have advanced [...]
Great News for the Advanced Prostate Cancer Community – The FDA Grants a Priority Review for Radium-223 Dichloride (Alpharadin)
Some more good news for the advanced prostate cancer community was announced today. Bayer HealthCare announced that the U.S. Food and Drug Administration (FDA) has granted priority review to their New Drug Application (NDA) filed [...]
Knowing Good from Bad Information Published on the Internet
We all use the Internet to learn about our prostate cancer, your reading this post confirms this statement. The Internet can be a useful tool for finding information and connecting with other patients and caregivers. [...]